2Y3-95398-54136
2 vaccinations
1 coded response
24 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 21-25
- ZIP prefix
- 720 / AR
- Registered
- 2021-09-04
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-09-03
Dose 1 — Pfizer-BioNTech
-
2021-09-04
Registered in v-safe
- 2021-09-04
- 2021-09-05
- 2021-09-06
- 2021-09-07
- 2021-09-08
- 2021-09-09
- 2021-09-10
- 2021-09-17
-
2021-09-24
Dose 2 — Pfizer-BioNTech
- 2021-09-24
- 2021-09-25
- 2021-09-26
- 2021-09-27
- 2021-09-28
- 2021-09-29
- 2021-09-30
- 2021-10-01
- 2021-10-08
- 2021-10-15
- 2021-10-22
- 2021-10-29
-
2021-11-05
Survey response — day 42, dose 2MedDRA: Malignant melanoma — Feeling: GoodFree text: Diagnosed with melanomaMedDRA releases: 2024-11 · check-in free text available
- 2021-12-24
- 2022-03-25
- 2022-09-24
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-09-03 | Pfizer-BioNTech | No |
| 2 | 2021-09-24 | Pfizer-BioNTech | No |
Free text
Release 10 — day 42, dose 2
Symptoms: Diagnosed with melanoma
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Malignant melanoma | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release